Dova Pharmaceuticals, Inc.
(NASDAQ GS: DOVA)
Attention investors who purchased shares of Dova Pharmaceuticals, Inc. before September 30, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Dova Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Swedish Orphan Biovitrum AB.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Dova Pharmaceuticals, Inc. (“Dova” or the “Company”) (NASDAQ GS: DOVA) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Swedish Orphan Biovitrum AB. Under the terms of the agreement, shareholders of Dova will receive $27.50 in cash and one Contigent Value Right (CVR) that entitles them to $1.50 for each share of Dova they own.
If you own common stock of Dova and purchased any shares before September 30, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at email@example.com, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.